Evaluation of the ResistancePlus GC (beta) assay: a commercial diagnostic test for the direct detection of ciprofloxacin susceptibility or resistance in Neisseria gonorrhoeae
Samantha Ebeyan, Madeline Windsor, Amanda Bordin, Lebogang Mhango, Simon Erskine, Ella Trembizki, Elisa Mokany, Lit Yeen Tan, David Whiley, Rebecca Guy, Rebecca Guy, Handan Wand, Basil Donovan, Stephen Bell, John Kaldor, Marlene Kong, Damian Conway, Lise Lafferty, James Ward, Monica Lahra Show all
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | OXFORD UNIV PRESS | Published : 2019
OBJECTIVES: To evaluate the performance of the ResistancePlus GC (beta) assay for the simultaneous detection of Neisseria gonorrhoeae and gyrA S91 markers of resistance (S91F) and susceptibility (WT) to ciprofloxacin, from both clinical specimens and isolates. METHODS: Performance was assessed on several sample banks, including N. gonorrhoeae isolates (n = 822), non-gonococcal isolates (n = 110), N. gonorrhoeae-positive clinical specimens (n = 402) and N. gonorrhoeae-negative specimens (n = 290). Results were compared with previous testing data, including S91 genotyping and phenotypic resistance profiles. RESULTS: Overall, the assay demonstrated 100% sensitivity for N. gonorrhoeae detection ..View full abstract
Awarded by National Health and Medical Research Council (NHMRC)
This study was funded by the National Health and Medical Research Council (NHMRC) (GNT01122141) and SpeeDx Pty Ltd; David Whiley is a recipient of an NHMRC fellowship.